Loading stock data…
$36.89+0.32 (+0.88%)
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Genmab A/S in the Healthcare sector is trading at $36.89 with a market capitalization of $19.9B. Wall Street consensus targets $44.40 (11 analysts), implying a +20.4% move over the next 12 months. The stock is currently near its 52-week high of $40.17, remaining 23.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.16B↑ | $896.00M↓ | $1.06B↑ | $1.02B↑ | $925.00M |
| Gross Profit | $1.07B↑ | $831.00M↓ | $977.00M↑ | $964.00M↑ | $868.00M |
| Operating Income | $407.00M↑ | $225.00M↓ | $243.00M↓ | $459.00M↑ | $360.00M |
| Net Income | $303.00M↑ | $53.00M↑ | $31.00M↓ | $401.00M↑ | $336.00M |
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diff...